Cliff Asness AQR Capital Management
Cliff Asness is a co-founder of AQR Capital Management, a leading quantitative investment firm spanning equities, alternatives, and factor strategies. He is known for academic-informed research on value, momentum, and other systematic premia, as well as candid market commentary. Asness’s work bridges academic finance and large-scale institutional portfolio management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.58% |
| 2 | Healthcare | 16.26% |
| 3 | Financials | 11.97% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
Atea Pharmaceuticals
AVIR
$442M
| $726K | ﹤0.01% |
150,888
+120,376
| +395% | +$609K |
|
1677
Acadia Pharmaceuticals
ACAD
$5.11B
| $723K | ﹤0.01% |
45,434
+5,531
| +14% | +$86.5K |
|
|
STR
1678
DELISTED
Sitio Royalties
STR
| $721K | ﹤0.01% |
25,008
+14,086
| +129% | +$408K |
|
|
CCF
1679
DELISTED
Chase Corporation
CCF
| $720K | ﹤0.01% |
8,346
-689
| -8% | -$62K |
|
1680
AngioDynamics
ANGO
$652M
| $719K | ﹤0.01% |
52,200
+36,023
| +223% | +$501K |
|
|
LTHM
1681
DELISTED
Livent Corporation
LTHM
| $717K | ﹤0.01% |
36,095
+4,162
| +13% | +$114K |
|
1682
Vital Farms
VITL
$476M
| $717K | ﹤0.01% |
48,024
-48,217
| -50% | -$665K |
|
|
BRSL
1683
Brightstar Lottery PLC
BRSL
$2.16B
| $714K | ﹤0.01% |
31,494
+16,530
| +110% | +$358K |
|
1684
Piper Sandler
PIPR
$5.29B
| $713K | ﹤0.01% |
21,912
-52,712
| -71% | -$1.72M |
|
1685
AdaptHealth
AHCO
$751M
| $710K | ﹤0.01% |
36,964
+25,149
| +213% | +$532K |
|
1686
MacroGenics
MGNX
$256M
| $708K | ﹤0.01% |
105,548
-430,783
| -80% | -$2.36M |
|
1687
Brookfield Renewable
BEPC
$6.1B
| $707K | ﹤0.01% |
+25,685
| New | +$793K |
|
1688
IDT Corp
IDT
$1.7B
| $703K | ﹤0.01% |
24,957
-4,798
| -16% | -$129K |
|
1689
Axalta
AXTA
$7.72B
| $703K | ﹤0.01% |
27,857
-82
| -0.3% | -$2.03K |
|
1690
Nabors Industries
NBR
$1.31B
| $700K | ﹤0.01% |
4,523
-7,447
| -62% | -$1.11M |
|
|
BGFV
1691
DELISTED
Big 5 Sporting Goods
BGFV
| $699K | ﹤0.01% |
+79,206
| New | +$911K |
|
|
SHOE
1692
Shoe Station Group
SHOE
$424M
| $699K | ﹤0.01% |
29,243
-30,678
| -51% | -$733K |
|
1693
Northeast Bank
NBN
$1.11B
| $697K | ﹤0.01% |
16,557
-8,437
| -34% | -$355K |
|
1694
OneSpan
OSPN
$575M
| $697K | ﹤0.01% |
62,266
-71,524
| -53% | -$822K |
|
1695
Insmed
INSM
$27.1B
| $692K | ﹤0.01% |
34,624
+6,726
| +24% | +$130K |
|
1696
Citi Trends
CTRN
$619M
| $690K | ﹤0.01% |
26,069
+14,619
| +128% | +$344K |
|
1697
DoorDash
DASH
$99.3B
| $687K | ﹤0.01% |
14,076
-96,674
| -87% | -$5.02M |
|
|
XHR
1698
Xenia Hotels & Resorts
XHR
$1.81B
| $686K | ﹤0.01% |
52,079
+15,092
| +41% | +$225K |
|
1699
Home BancShares
HOMB
$6.01B
| $686K | ﹤0.01% |
30,093
-1,020
| -3% | -$24.7K |
|
1700
A10 Networks
ATEN
$1.83B
| $683K | ﹤0.01% |
41,069
-112,287
| -73% | -$1.92M |
|
Similar funds
Cliff Asness's Q4 2022 Portfolio in Review
As of Q4 2022, Cliff Asness held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Cliff Asness's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- Cliff Asness's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- Cliff Asness added most to Humana in Q4 2022, an estimated $111M increase.
- Cliff Asness's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- Cliff Asness fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- Cliff Asness's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- Cliff Asness opened 170 new positions and closed 150 in Q4 2022.
- Cliff Asness's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.